Retrotransposon mobilization in cancer genomes
Tracy Ballinger, Adam D. Ewing, David Haussler

TL;DR
This study developed a computational method to detect somatic retrotransposon insertions in cancer genomes, revealing activity mainly in colorectal cancer and not in glioblastoma or ovarian cancers.
Contribution
The paper introduces a highly efficient pipeline for detecting non-reference mobile element insertions from whole genome sequencing data in cancer, highlighting tissue-specific retrotransposon activity.
Findings
Detected 72 insertions in colon cancer, mostly LINE-1 elements.
No somatic retrotransposon insertions found in glioblastoma or ovarian cancers.
Retrotransposon activity varies widely among samples, with some cases showing many insertions.
Abstract
The Cancer Genome Atlas project was initiated by the National Cancer Institute in order to characterize the genomes of hundreds of tumors of various cancer types. While much effort has been put into detecting somatic genomic variation in these data, somatic structural variation induced by the activity of transposable element insertions has not been reported. Transposable elements (TEs) are particularly relevant in cancer in part because of several known cases in which a TE insertion is directly linked to cancer formation and studies linking the epigenetic status of retrotransposons to carcinogenesis and patient outcome. Additionally, evidence for somatic retrotransposition in eukaryotic genomes suggests that some tissues and therefore some cancer types may be disposed to increased retrotransposition. We built upon previous work to develop a highly efficient computational pipeline for…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsChromosomal and Genetic Variations · Genomic variations and chromosomal abnormalities · CRISPR and Genetic Engineering
